Clinical Trials Logo

Nervous System Neoplasms clinical trials

View clinical trials related to Nervous System Neoplasms.

Filter by:

NCT ID: NCT00017264 Completed - Clinical trials for Brain and Central Nervous System Tumors

Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma

Start date: June 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of atrasentan in treating patients who have progressive or recurrent malignant glioma.

NCT ID: NCT00016991 Completed - Clinical trials for Brain and Central Nervous System Tumors

ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse

Start date: June 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have glioblastoma multiforme in first relapse.

NCT ID: NCT00015899 Completed - Clinical trials for Brain and Central Nervous System Tumors

SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors

Start date: January 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.

NCT ID: NCT00014677 Completed - Clinical trials for Brain and Central Nervous System Tumors

NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: March 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: NBI-3001 may be able to locate cancer cells and stop them from growing. This may be an effective treatment for glioblastoma multiforme. PURPOSE: Randomized phase II trial to compare different regimens of NBI-3001 followed by surgery to remove the tumor in treating patients who have glioblastoma multiforme.

NCT ID: NCT00014573 Completed - Clinical trials for Brain and Central Nervous System Tumors

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Start date: August 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Vaccines made from a person's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and vaccine therapy followed by bone marrow or peripheral stem cell transplantation and interleukin-2 in treating patients who have recurrent or refractory brain cancer.

NCT ID: NCT00014521 Completed - Clinical trials for Brain and Central Nervous System Tumors

Karenitecin in Treating Patients With Recurrent Malignant Glioma

Start date: January 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of karenitecin in treating patients who have recurrent malignant glioma.

NCT ID: NCT00014443 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Start date: August 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of combining topotecan and thalidomide in treating patients who have recurrent or refractory malignant glioma.

NCT ID: NCT00014300 Completed - Clinical trials for Brain and Central Nervous System Tumors

Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: January 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of glufosfamide in treating patients who have recurrent glioblastoma multiforme.

NCT ID: NCT00014105 Active, not recruiting - Clinical trials for Brain and Central Nervous System Tumors

Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: December 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients who have recurrent glioblastoma multiforme.

NCT ID: NCT00012038 Completed - Clinical trials for Brain and Central Nervous System Tumors

Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors

Start date: July 2001
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irofulven in treating patients who have progressive or recurrent astrocytoma, oligodendroglioma, or glioblastoma multiforme.